Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Infect Immun ; 81(6): 1984-9, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23509152

RESUMO

Pfs25 is a leading candidate for a malaria transmission-blocking vaccine whose potential has been demonstrated in a phase 1 trial with recombinant Pfs25 formulated with Montanide ISA51. Because of limited sequence polymorphism, the anti-Pfs25 antibodies induced by this vaccine are likely to have transmission-blocking or -reducing activity against most, if not all, field isolates. To test this hypothesis, we evaluated transmission-blocking activities by membrane feeding assay of anti-Pfs25 plasma from the Pfs25/ISA51 phase 1 trial against Plasmodium falciparum parasites from patients in two different geographical regions of the world, Thailand and Burkina Faso. In parallel, parasite isolates from these patients were sequenced for the Pfs25 gene and genotyped for seven microsatellites. The results indicate that despite different genetic backgrounds among parasite isolates, the Pfs25 sequences are highly conserved, with a single nonsynonymous nucleotide polymorphism detected in 1 of 41 patients in Thailand and Burkina Faso. The anti-Pfs25 immune plasma had significantly higher transmission-reducing activity against parasite isolates from the two geographical regions than the nonimmune controls (P < 0.0001).


Assuntos
Anticorpos Antiprotozoários/imunologia , Vacinas Antimaláricas/imunologia , Malária Falciparum/transmissão , Plasmodium falciparum/genética , Proteínas de Protozoários/imunologia , Animais , Anopheles/parasitologia , Burkina Faso/epidemiologia , Variação Genética , Humanos , Soros Imunes/imunologia , Malária Falciparum/epidemiologia , Malária Falciparum/parasitologia , Repetições de Microssatélites , Plasmodium falciparum/imunologia , Tailândia/epidemiologia
2.
Nat Genet ; 48(8): 953-8, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27348298

RESUMO

Plasmodium vivax is a major public health burden, responsible for the majority of malaria infections outside Africa. We explored the impact of demographic history and selective pressures on the P. vivax genome by sequencing 182 clinical isolates sampled from 11 countries across the globe, using hybrid selection to overcome human DNA contamination. We confirmed previous reports of high genomic diversity in P. vivax relative to the more virulent Plasmodium falciparum species; regional populations of P. vivax exhibited greater diversity than the global P. falciparum population, indicating a large and/or stable population. Signals of natural selection suggest that P. vivax is evolving in response to antimalarial drugs and is adapting to regional differences in the human host and the mosquito vector. These findings underline the variable epidemiology of this parasite species and highlight the breadth of approaches that may be required to eliminate P. vivax globally.


Assuntos
Resistência a Medicamentos/genética , Marcadores Genéticos/genética , Malária Vivax/parasitologia , Metagenômica/métodos , Plasmodium vivax/genética , Seleção Genética/genética , Transcriptoma/genética , Antimaláricos/farmacologia , Humanos , Malária Vivax/tratamento farmacológico , Malária Vivax/genética , Plasmodium vivax/efeitos dos fármacos , Plasmodium vivax/patogenicidade , Seleção Genética/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA